Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine.
SARS-CoV-2 mRNA vaccine
T cell response
adverse effects
dynamics of the immune response
spike RBD-ACE2 inhibition
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
16 08 2022
16 08 2022
Historique:
received:
06
03
2022
revised:
14
06
2022
accepted:
19
07
2022
pubmed:
12
8
2022
medline:
20
8
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
The high number of mutations in the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes its immune escape. We report a longitudinal analysis of 111 vaccinated individuals for their antibody levels up to 6 months after the third dose of the BNT162b2 vaccine. After the third dose, the antibody levels decline but less than after the second dose. The booster dose remarkably increases the serum ability to block wild-type or Omicron variant spike protein's receptor-binding domain (RBD) interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, and these protective antibodies persist 3 months later. Three months after the booster dose, memory CD4
Identifiants
pubmed: 35952669
pii: S2666-3791(22)00259-2
doi: 10.1016/j.xcrm.2022.100716
pmc: PMC9350667
pii:
doi:
Substances chimiques
Antibodies
0
Spike Glycoprotein, Coronavirus
0
Vaccines
0
Viral Envelope Proteins
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100716Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Cell Discov. 2022 Feb 1;8(1):10
pubmed: 35102140
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
N Engl J Med. 2021 Jul 29;385(5):472-474
pubmed: 33979486
Mol Biol Evol. 2022 Apr 11;39(4):
pubmed: 35325204
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Euro Surveill. 2022 Jan;27(4):
pubmed: 35086614
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2022 Mar 17;185(6):1041-1051.e6
pubmed: 35202566
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Sci Rep. 2022 Mar 3;12(1):3549
pubmed: 35241780
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482